The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identifying optimized assessment of nerve damage during chemotherapy.
 
Tiffany Li
No Relationships to Disclose
 
Hannah C Timmins
No Relationships to Disclose
 
Fawaz Mayez Mahfouz
No Relationships to Disclose
 
David Mizrahi
No Relationships to Disclose
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology; Pfizer
 
Michelle L. Harrison
Stock and Other Ownership Interests - CSL Limited (I)
 
Peter S. Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Genentech (Inst); InhibRx (Inst); InhibRx (Inst); Janssen-Cilag (Inst); MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Michael Friedlander
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Novartis
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Incyclix Bio; Lilly; MSD; Novartis; Takeda
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst)
 
Gavin M. Marx
No Relationships to Disclose
 
Frances M. Boyle
Honoraria - AstraZeneca; Eisai; Gilead Sciences; Lilly; Roche
Consulting or Advisory Role - Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Expert Testimony - Gilead Sciences; Lilly
Travel, Accommodations, Expenses - Novartis
Other Relationship - Pamgene; Paxman
(OPTIONAL) Uncompensated Relationships - Paxman; Paxman
 
David Wyld
Consulting or Advisory Role - Ipsen; Novartis; Novartis
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; MSD Oncology; Novartis; Novartis; Novartis
 
Robert Henderson
Honoraria - Biogen; Genzyme
Consulting or Advisory Role - Biogen; Genzyme
Speakers' Bureau - Genzyme
 
Tracy King
Consulting or Advisory Role - Janssen Oncology
 
Sally E. Baron-Hay
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck Sharpe and Doehme; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; MSD Oncology
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences; MSD Oncology; Novartis
 
Matthew C Kiernan
No Relationships to Disclose
 
Claudia Rutherford
Research Funding - Little Green Pharma Ltd (Inst)
 
David Goldstein
Honoraria - AstraZeneca; Boehringer Ingelheim; Sun Biopharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; duo oncology; hC bioscience; Medison; MSD Oncology; Seagen; sun biopharma; Takeda
Research Funding - Amgen (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); pfizer (Inst); Zucero Therapeutics (Inst)
 
Susanna B Park
No Relationships to Disclose